Stellar Biotechnologies Exceeds Aquaculture Capacity Goals
PORT HUENEME, CA, Feb 19, 2013 (MARKETWIRE via COMTEX) --
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB:
SBOTF) (TSX VENTURE: KLH) today announced that the Company exceeded
its 2012 plan to increase key stages of its aquaculture capacity to
prepare for future demand for Keyhole Limpet Hemocyanin (KLH).
For the year ending 2012, Stellar exceeded its aquaculture hatchery
goal by nearly 30%, the combined result of expanded facilities and
new methods related to the cultivation of the Giant Keyhole Limpet
The Giant Keyhole Limpet is a scarce sea mollusk and the sole source
for KLH, a vitally important, immune-stimulating protein
Following expansion of Stellar's physical plant in 2011, the Company
developed new and proprietary methods for cultivating limpets that
ensures unprecedented survival rates of this important natural
resource. Stellar's hatchery innovations and controlled conditions
have optimized the Company's production; increasing yields and
setting the stage for long-term KLH capacity while reducing
The net result, given sufficient funding, is to accelerate Stellar's
projected KLH production capacity to as much as 5 kilograms per year
within the next four years, to 20 kilograms per year a few years
"This positions Stellar as the only company that will be capable of
supplying GMP grade KLH that can meet the anticipated long-term
demand within the pharmaceutical industry," said Frank Oakes,
President and CEO. "This is a testament to our customer focus and
"Exceeding aquaculture capacity ahead of schedule means we will be
prepared to ensure scalable supplies of the highest quality KLH for
our pharmaceutical partners," said Brandon Lincicum, Stellar
Executive Director of Aquaculture.
For more information:
Visit www.StellarBiotech.com and the KLH
knowledge base www.KLHSite.com.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc.
(OTCQB: SBOTF) (TSX VENTURE: KLH) is the world leader in sustainable
manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important
immune-stimulating protein used in wide-ranging therapeutic and
diagnostic markets. Potent, yet proven safe in humans, KLH operates
as both a vital component for conjugate vaccines (targeting cancer,
autoimmune, and infectious diseases) as well as an antigen for
measuring immune status. Stellar Biotechnologies was founded to
address the growing demand for renewable, commercial-scale supplies
of high-quality, GMP-grade KLH. Stellar has developed leading
practices, facilities and proprietary capabilities to address this
need. To receive regular updates, enter email at bottom of
Forward Looking Statements
There can be no assurance that forward-looking statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Readers should
not place undue reliance on such statements. Except in accordance
with applicable securities laws, the Company expressly disclaims any
obligation to update any forward-looking statements or
forward-looking statements that are incorporated by reference herein.
This news release does not constitute an offer to sell, or a
solicitation of an offer to buy any of the Company's securities set
out herein in the United States, or to, or for the benefit or account
of, a U.S. Person or person in the United States. Neither TSX Venture
Exchange nor its Regulation Services Provider accepts responsibility
for the adequacy or accuracy of these releases.
Stellar Biotechnologies, Inc.
Executive VP, Corporate Development & Finance
Main +1 (805) 488-2800
Mark A. McPartland
Senior Vice President
Phone: 1 212-301-7130
SOURCE: Stellar Biotechnologies, Inc.
[ Back To Technology News's Homepage ]